These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 20538015)

  • 1. HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.
    Wissing S; Galloway NL; Greene WC
    Mol Aspects Med; 2010 Oct; 31(5):383-97. PubMed ID: 20538015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins.
    Zhang W; Chen G; Niewiadomska AM; Xu R; Yu XF
    PLoS One; 2008; 3(12):e3963. PubMed ID: 19088851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.
    Baig TT; Feng Y; Chelico L
    J Virol; 2014 Dec; 88(24):14380-95. PubMed ID: 25275135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.
    Zhang W; Huang M; Wang T; Tan L; Tian C; Yu X; Kong W; Yu XF
    Cell Microbiol; 2008 Aug; 10(8):1662-75. PubMed ID: 18419775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
    Binka M; Ooms M; Steward M; Simon V
    J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
    Albin JS; Harris RS
    Expert Rev Mol Med; 2010 Jan; 12():e4. PubMed ID: 20096141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.
    Siu KK; Sultana A; Azimi FC; Lee JE
    Nat Commun; 2013; 4():2593. PubMed ID: 24185281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Vif, APOBEC, and intrinsic immunity.
    Goila-Gaur R; Strebel K
    Retrovirology; 2008 Jun; 5():51. PubMed ID: 18577210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase.
    Fribourgh JL; Nguyen HC; Wolfe LS; Dewitt DC; Zhang W; Yu XF; Rhoades E; Xiong Y
    J Virol; 2014 Mar; 88(6):3309-19. PubMed ID: 24390320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
    Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F.
    Albin JS; Anderson JS; Johnson JR; Harjes E; Matsuo H; Krogan NJ; Harris RS
    J Mol Biol; 2013 Apr; 425(7):1172-82. PubMed ID: 23318957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain.
    Bohn MF; Shandilya SM; Albin JS; Kouno T; Anderson BD; McDougle RM; Carpenter MA; Rathore A; Evans L; Davis AN; Zhang J; Lu Y; Somasundaran M; Matsuo H; Harris RS; Schiffer CA
    Structure; 2013 Jun; 21(6):1042-50. PubMed ID: 23685212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.
    Münk C; Jensen BE; Zielonka J; Häussinger D; Kamp C
    Viruses; 2012 Nov; 4(11):3132-61. PubMed ID: 23202519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.
    Richards C; Albin JS; Demir Ö; Shaban NM; Luengas EM; Land AM; Anderson BD; Holten JR; Anderson JS; Harki DA; Amaro RE; Harris RS
    Cell Rep; 2015 Dec; 13(9):1781-8. PubMed ID: 26628363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Wang X; York IA; Zheng YH
    J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV restriction by APOBEC3 in humanized mice.
    Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
    PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.